Snap Inc vs Twist Bioscience Corp — how do they compare? Snap Inc trades at $4.58 (market cap $7.67B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Snap Inc is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals.
| SNAP | TWST | |
|---|---|---|
Market Cap | $7.67B | $5.45B |
Sector | Media | Health |
52-Week High | $10.35 | $102.88 |
52-Week Low | $3.93 | $24.16 |
Enterprise Value | $9.05B | $5.37B |
Signals from Pluang's Aura AI — not financial advice
Snap Inc. (SNAP) trades at $4.56, up 0.77% on the day, with a bearish technical signal and mixed fundamentals. Revenue grew to $5.93B in 2025, but net losses persist at -$460M. The stock shows improving cash flow from operations and has beaten EPS estimates in recent quarters. Analyst consensus is a 'Hold' with a $5.83 price target, suggesting modest upside from current levels.
The outlook remains cautious due to ongoing losses and competitive pressures, though cost-cutting and AR initiatives offer potential. Key risks include high debt, regulatory scrutiny, and uncertain demand for new products like SPECS glasses. Upside depends on sustained user engagement and profitability improvements.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →